Single-nucleotide polymorphisms (SNPs) in human β-defensin 1: High-throughput SNP assays and association with Candida carriage in type I diabetics and nondiabetic controls

Journal of Clinical Microbiology

Volumn 41, Issue 1, 2003, Pages 90-96

  Jurevic, Richard J ^a   Bai, Mai ^a   Chadwick, Robert B ^a   White, Theodore C ^a   Dale, Beverly A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA DEFENSIN; BETA DEFENSIN 1; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS; CLINICAL ARTICLE; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE CARRIER; FEMALE; GENE AMPLIFICATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; INFECTION SENSITIVITY; INSULIN DEPENDENT DIABETES MELLITUS; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; ORAL BIOPSY; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA TROPICALIS;

EID: 0037231945     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.41.1.90-96.2003     Document Type: Article

References (44)

1. Andriole, V. T. 1999. The 1998 Garrod lecture. Current and future antifungal therapy: new targets for antifungal agents. J. Antimicrob. Chemother. 44:151-162.
2. Bensch, K. W., M. Raida, H. J. Magert, K.-P. Schulz, and W. G. Forssmann. 1995. hBD 1: a novel beta defensin from human plasma. FEBS Lett. 368:331-335.
3. Boman, H. G. 1998. Gene encoded peptide antibiotics and the concept of innate immunity: an update review. Scand. J. Immunol. 48:15-25.
4. Cannon, R. D., and W. L. Chaffin. 1999. Oral colonization by Candida albicans. Crit. Rev. Oral Biol. Med. 10:359-383.
5. Cannon, R. D., A. R. Holmes, A. B. Mason, and B. C. Monk. 1995. Oral Candida: clearance, colonization, or candidiasis? J. Dent. Res. 74:1152-1161.
6. Circo, R., B. Skerlavaj, R. Gennaro, A. Amoroso, and M. Zanetti. 2002. Structural and functional characterization of hBD-1(Ser35), a peptide deduced from a DEFB1 polymorphism. Biochem. Biophys. Res. Commun. 293:586-592.
7. Dork, T. S. M. 1998. Polymorphisms of the human B-defensin gene. Mol. Cell. Probes 12:171-173.
8. Ganz, T., and R. I. Lehrer. 1998. Antimicrobial peptides of vertebrates. Curr. Opin. Immunol. 10:41-44.
9. Garcia, J. R., A. Krause, S. Schulz, F. J. Rodriguez-Jimenez, E. Kluver, K. Adermann, U. Forssmann, A. Frimpong-Boateng, R. Bals, and W. G. Forssmann. 2001. Human beta-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. FASEB J. 15:1819-1821.
10. Goswami, R., V. Dadhwal, S. Tejaswi, K. Datta, A. Paul, R. N. Haricharan, U. Banerjee, and N. P. Kochupillai. 2000. Species-specific prevalence of vaginal candidiasis among patients with diabetes mellitus and its relation to their glycaemic status. J. Infect. 41:162-166.
11. Greenspan, D., and J. S. Greenspan. 1996. HIV related oral disease. Lancet 348:729-733.
12. Guggenheimer, J., P. A. Moore, K. Rossie, D. Myers, M. B. Mongelluzzo, H. M. Block, R. Weyant, and T. Orchard. 2000. Insulin-dependent diabetes mellitus and oral soft tissue pathologies. I. Prevalence and characteristics of non-candidal lesions. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 89:563-569.
13. Guggenheimer, J., P. A. Moore, K. Rossie, D. Myers, M. B. Mongelluzzo, H. M. Block, R. Weyant, and T. Orchard. 2000. Insulin-dependent diabetes mellitus and oral soft tissue pathologies. II. Prevalence and characteristics of Candida and candidal lesions. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 89:570-576.
14. Harder, J., J. Bartels, E. Christophers, and J. M. Schroder. 1997. A peptide antibiotic from human skin. Nature 387:861.
15. Hill, L. V., M. H. Tan, L. H. Pereira, and J. A. Embil. 1989. Association of oral candidiasis with diabetic control. J. Clin. Pathol. 42:502-505.
16. Horowitz, S., R. Osborne, and F. DeGeorge. 1958. Caries experience in twins. Science 128:300-301.
17. Hostetter, M. K. 1990. Handicaps to host defense. Effects of hyperglycemia on C3 and Candida albicans. Diabetes 39:271-275.
18. Jurevic, R. J., P. Chrisman, L. Mancl, R. Livingston, and B. A. Dale. 2002. Single nucleotide polymorphisms in β-defensin genes in different ethnic populations. Genet. Test. 6:261-269.
19. Krisanaprakornkit, K., J. R. Kimball, A. Weinberg, R. P. Darveau, B. W. Bainbridge, and B. A. Dale. 2000. Inducible expression of human β-defensin-2 by Fusobacterium nucleatum in oral epithelial cells: multiple signaling pathways and the role of commensal bacteria in innate immunity and the epithelial barrier. Infect. Immun. 68:2907-2915.
20. Krisanaprakornkit, S., A. Weinberg, C. N. Perez, and B. A. Dale. 1998. Expression of the peptide antibiotic human beta-defensin 1 in cultured gingival epithelial cells and gingival tissue. Infect. Immun. 66:4222-4228.
21. Lamey, P. J., A. Darwaza, B. M. Fisher, L. P. Samaranayake, T. W. Macfarlane, and B. M. Frier. 1988. Secretor status, candidal carriage and candidal infection in patients with diabetes mellitus. J. Oral Pathol. 17:354-357.
22. Lehrer, R. I., and T. Ganz. 1996. Endogenous vertebrate antibiotics. Defensins, protegrins, and other cysteine rich antimicrobial peptides. Ann. N. Y. Acad. Sci. 797:228-239.
23. Lin, L., C. Zhao, H. H. Q. Heng, and T. Ganz. 1997. The human beta defensin-1 and alpha-defensins are encoded by adjacent genes: two families with differing disulfide topology share a common ancestry. Genomics 43:316-320.
24. Lockhart, S. R., S. Joly, K. Vargas, J. Swails-Wenger, L. Enger, and D. R. Soll. 1999. Natural defenses against Candida colonization breakdown in the oral cavities of the elderly. J. Dent. Res. 78:857-868.
25. Mathews, M., H. P. Jla, J. M. Guthmiller, G. Losh, S. Graham, G. K. Johnson, B. F. Tack, and P. B. McCray, Jr. 1999. Production of beta-defensin antimicrobial peptides by the oral mucosa and salivary glands. Infect. Immun. 67:2740-2745.
26. Matsushita, I., K. Hasegawa, K. Nakata, K. Yasuda, K. Tokunaga, and N. Keicho. 2002. Genetic variants of human beta-defensin-1 and chronic obstructive pulmonary disease. Biochem. Biophys. Res. Commun. 291:17-22.
27. Matsuzaki, K. 2001. Development of novel antimicrobial peptides: emerging strategies. Horizon Scientific Press, Wymondham, United Kingdom.
28. Odds, F. C. 1993. Resistance of yeasts to azole-derivative antifungals. J. Antimicrob. Chemother. 31:463-471.
29. Odds, F. C., and R. Bernaerts. 1994. CHROMagar Candida, a new differential isolation medium for presumptive identification of clinically important Candida species. J. Clin. Microbiol. 32:1923-1929.
30. Samaranayake, L. P. 1997. Candida krusei infections and fluconazole therapy. Hong Kong Med. J. 3:312-314.
31. Samaranayake, L. P. 1990. Oral candidosis: an old disease in new guises. Dent. Update 17:36-38.
32. Samaranayake, Y. H., L. P. Samaranayake, E. H. Pow, V. T. Beena, and K. W. Yeung. 2001. Antifungal effects of lysozyme and lactoferrin against genetically similar, sequential Candida albicans isolates from a human immunodeficiency virus-infected southern Chinese cohort. J. Clin. Microbiol. 39:3296-3302.
33. Schutte, B. C., J. P. Mitros, J. A. Bartlett, J. D. Walters, H. P. Jia, M. J. Welsh, T. L. Casavant, and P. B. McCray, Jr. 2002. Discovery of five conserved beta-defensin gene clusters using a computational search strategy. Proc. Natl. Acad. Sci. USA 99:2129-2133.
34. Snider, J. 1999. PCR applications: protocols for functional genomics. Academic Press, Inc., New York, N.Y.
35. Tapper-Jones, L. M., M. J. Aldred, D. M. Walker, and T. M. Hayes. 1981. Candidal infections and populations of Candida albicans in mouths of diabetics. J. Clin. Pathol. 34:706-711.
36. Tsai, H., and L. A. Bobek. 1998. Human salivary histatins: promising antifungal therapeutic agents. Crit. Rev. Oral Biol. Med. 9:480-497.
37. Ueta, E., T. Tanida, K. Yoneda, T. Yamamoto, and T. Osaki. 2001. Increase of Candida cell virulence by anticancer drugs and irradiation. Oral Microbiol. Immunol. 16:243-249.
38. Valore, E. V., C. H. Park, A. J. Quayle, K. R. Wiles, P. B. McCray, Jr., and T. Ganz. 1998. Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. J. Clin. Investig. 101:1633-1642.
39. Vatta, S., M. Boniotto, E. Bevilacqua, A. Belgrano, D. Pirulli, S. Crovella, and A. Amoroso. 2000. Human beta defensin 1 gene: six new variants. Hum. Mutat. 15:582-583.
40. Weinberg, A., S. Krisanaprakornkit, and B. A. Dale. 1998. Epithelial antimicrobial peptides: review and significance for oral applications. Crit. Rev. Oral Biol. Med. 9:399-414.
41. White, T. C., K. A. Marr, and R. A. Bowden. 1998. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:382-402.
42. Willis, A. M., W. A. Coulter, C. R. Fulton, J. R. Hayes, P. M. Bell, and P. J. Lamey. 2001. The influence of antifungal drugs on virulence properties of Candida albicans in patients with diabetes mellitus. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 91:317-321.
43. Willis, A. M., W. A. Coulter, C. R. Fulton, J. R. Hayes, P. M. Bell, and P. J. Lamey. 1999. Oral candidal carriage and infection in insulin-treated diabetic patients. Diabet. Med. 16:675-679.
44. Zhao, C., I. Wang, and R. I. Lehrer. 1996. Widespread expression of beta-defensin hBD-1 in human secretory glands and epithelial cells. FEBS Lett. 396:319-322.